Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110

Benzinga · 1d ago
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.